A modified DCF regimen as primary treatment for patients with metastatic gastric cancer

• Published in: Journal of B.U. ON. Vol. 18; no. 2; p. 377
• Main Authors: Koca, D, Dogan, E, Yardim, H, Duzen, O, Karaca, S
• Format: Journal Article
• Language: English
• Published: Greece 01-04-2013
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma - drug therapy; Carcinoma - mortality; Carcinoma - secondary; Chi-Square Distribution; Cisplatin - administration & dosage; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil - administration & dosage; Humans; Kaplan-Meier Estimate; Leucovorin - administration & dosage; Male; Middle Aged; Neutropenia - chemically induced; Retrospective Studies; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Taxoids - administration & dosage; Time Factors; Treatment Outcome
• ISSN: 1107-0625

To retrospectively assess the efficacy and toxity of a modified docetaxel, cisplatin, fluorouracil (mDCF) regimen as primary treatment in patients with metastatic gastric cancer (MGC).
mDCF included folinic acid 400 mg/m(2) (day 1) + 5-fluorouracil (5-FU) 400 mg/m(2) i.v. bolus (day 1) + 5-FU 2400 mg/m(2) 46-h infusion (days 1 and 2) + docetaxel 60 mg/m(2) (day 1) + cisplatin 50 mg/m(2) (day 1) and was administered once every two weeks in MGC patients.
Eighty-nine patients (median age 59 years, range 31-79) were enrolled. The median number of courses was 6 (range 2-12), and the total number was 492. The median follow-up duration was 8.6 months (range 2-14). Three (3.3%) patients showed complete response, 21 (23.6%) partial response, 36 (40.4%) stable disease, and progression was observed in 29 (32.6%) patients. The median progression- free survival (PFS) rate was 7 months (95% CI 5.7-8.2), and the median overall survival (OS) rate was 11 months (95% CI 9.7-12.2). The most common toxicity was neutropenia, which was observed in 52 (58.4%) patients.
mDCF with reduced drug doses, given every two weeks, is a rather efficient regimen for MGC patients.